An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

  • End date
    Aug 23, 2025
  • participants needed
  • sponsor
Updated on 10 April 2023
bilateral oophorectomy


The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions.

The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and an Open-label Extension Treatment Period), and a Posttreatment Follow-up Period.


Permitted Concomitant Medications and Procedures

  • Subjects are receiving a JAK2 inhibitor for the treatment of MPN-associated MF that is approved in the country where the study is being conducted. JAK2 inhibitors are to be used according to their respective label and as prescribed as part of the subject's standard-of-care therapy as prescribed by their physician prior to study entry.
  • Best supportive care (BSC) includes, but is not limited to, treatment with transfusions (eg, RBC, platelet, whole blood), ICTs, antibiotic, antiviral and/or antifungal therapy, and nutritional support as needed.
  • Granulocyte colony-stimulating factors (ie, G-CSF, granulocyte macrophage colony-stimulating factor [GM-CSF]) are allowed only in cases of neutropenic fever or as clinically indicated per product label.
  • Prophylactic antithrombotic therapy is permitted.
  • Thrombopoietin and platelet transfusions are permitted.
  • Treatment with systemic corticosteroids is permitted for nonhematological conditions providing the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone during the study.
  • Administration of attenuated vaccines (eg, influenza vaccine) is allowed if clinically indicated per Investigator discretion.
  • Iron chelation therapy (ICT) is to be used according to the product label. If the label permits, the ICT dose should be stable during at least the first 24 weeks of IP. Initiation of ICT while within the first 24 weeks of IP should be clinically indicated to treat an AE.

Prohibited Concomitant Medications

The following concomitant medications are specifically excluded during the course of study

  • Cytotoxic, chemotherapeutic, targeted, or investigational agents/therapies (excluding JAK2 inhibitor therapy)
  • Azacitidine, decitabine, or other hypomethylating agents
  • Lenalidomide, thalidomide, and pomalidomide
  • Erythropoietin stimulating agents (ESAs) and other RBC hematopoietic growth factors (eg, IL-3)
  • Hydroxyurea or other alkylating agents
  • Androgens (unless given to treat hypogonadism)
  • Oral retinoids (topical retinoids are permitted)
  • Arsenic trioxide
  • Interferon
  • Anagrelide
  • Systemic corticosteroids at a dose equivalent to > 10 mg prednisone
  • Investigational products for the treatment of MPN-associated MF

Condition Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Anemia
Treatment Placebo, ACE-536
Clinical Study IdentifierNCT04717414
Last Modified on10 April 2023


Yes No Not Sure

Inclusion Criteria

Subjects must satisfy the following criteria to be randomized in the study
Subject is ≥18 years of age at the time of signing the ICF
Subject has a diagnosis of PMF according to the 2016 World Health Organization (WHO) criteria or diagnosis of post-ET or post-PV MF according to the IWG-MRT 2007 criteria , confirmed by the most recent local pathology report
Subject is requiring RBC transfusions as defined as
Average RBC-transfusion frequency: 4 to 12 RBC units/12 weeks immediately up to randomization. There must be no interval > 6 weeks (42 days) without ≥ 1 RBC transfusion
RBC transfusions are scored in determining eligibility when given for treatment of
Symptomatic (ie, fatigue or shortness of breath) anemia with a pretransfusion Hgb ≤ 9.5 g/dL or
Asymptomatic anemia with a pretransfusion Hgb ≤ 7 g/dL c. RBC transfusions given for worsening of anemia due to bleeding or infections are not scored in determining eligibility
Subjects on continuous (eg, absent of dose interruptions lasting ≥ 2 consecutive
weeks) JAK2 inhibitor therapy as approved in the country of the study site for
A female of childbearing potential (FCBP) for this study is defined as a female who
the treatment for MPN-associated MF as part of their standard-of-care therapy
has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (eg, has had menses at any time in the preceding 24 consecutive months). Females of childbearing potential (FCBP)participating in the study must
for at least 32 weeks, on stable daily dose for at least 16 weeks immediately
Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the study, and after end of IP. This applies even if the subject practices true abstinence from heterosexual contact
up to the date of randomization and anticipated to be on a stable daily dose
Either commit to true abstinence _from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception_ without interruption, 28 days prior to starting IP, during the study therapy (including dose interruptions), and for 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) after discontinuation of study therapy
of that JAK2 inhibitor for at least 24 weeks after randomization
Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2
True abstinence is acceptable when it is in line with the preferred and usual lifestyle of the subject. [Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.]
Agreement to use highly effective methods of contraception that alone or in
Male subjects must: Practice true abstinence _(which must be reviewed on a monthly
basis) or agree to use a condom during sexual contact with a pregnant female
or a female of childbearing potential_ while participating in the study
during dose interruptions and for at least 12 weeks (approximately 5 times the
mean terminal half-life of IP based on multiple-dose PK data) following IP
discontinuation, even if he has undergone a successful vasectomy
combination result in a failure rate of a Pearl index of less than 1% per year when
used consistently and correctly throughout the course of the study. Such methods
include: Combined (estrogen and progestogen containing) hormonal contraception: Oral
Intravaginal, Transdermal; Progestogen-only hormonal contraception associated with
inhibition of ovulation: Oral, Injectable hormonal contraception, Implantable hormonal
contraception; Placement of an intrauterine device (IUD); Placement of an intrauterine
hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomized partner
Sexual Abstinence
Subject must understand and voluntarily sign an ICF prior to any study-related
assessments/procedures being conducted
Subject is willing and able to adhere to the study visit schedule and other protocol
requirements including the use of the electronic patient reported outcomes device

Exclusion Criteria

Subject with any of the following laboratory abnormalities at screening
The presence of any of the following will exclude a subject from randomization
Subject with anemia from cause other than MPN-associated MForJAK2 inhibitor therapy
Peripheral blood myeloblasts:> 5%
(eg, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic
anemia, infection, or any type of known clinically significant bleeding or
Subject use of hydroxyurea, immunomodulatory compounds such as pomalidomide
thalidomide, ESAs, androgenic steroids or other drugs with potential effects on
hematopoiesis ≤ 8 weeks immediately up to the date of randomization
Systemic corticosteroids are permitted for nonhematological conditions providing
Basal or squamous cell carcinoma of the skin
the subject is receiving a constant dose equivalent to ≤ 10 mg prednisone for the
Carcinoma in situ of the cervix
weeks immediately up to randomization
Carcinoma in situ of the breast
Iron chelation therapy (ICT) is permitted providing the subject is receiving a
stable dose for the 8 weeks immediately up to randomization
Neutrophils: < 1 x 10^9/L
White blood count (WBC): > 100 x 10^9/L
Platelets: the lowest allowable level as approved for the concomitant JAK2
inhibitor but not < 25 x 10^9/L or > 1000 x 10^9/L
Estimated glomerular filtration rate:< 30 mL/min/1.73 m2 (via the 4-variable
modification of diet in renal disease [MDRD] formula) or nephrotic subjects (eg
urine albumin-to-creatinine ratio > 3500 mg/g)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT):> 3.0 x upper
limit of normal (ULN)
Direct bilirubin: ≥ 2 x ULN
Higher levels are acceptable if these can be attributed to active red blood
cell precursor destruction within the bone marrow (eg, ineffective
Subject with uncontrolled hypertension, defined as repeated elevations of systolic
blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, that is not resolved
at the time of randomization
Subject with prior history of malignancies, other than disease under study, unless the
subject has been free of the disease for ≥ 3 years. However, subject with the
following history/concurrent conditions is allowed
Incidental histologic finding of prostate cancer (T1a or T1b using the tumor
nodes, metastasis [TNM] clinical staging system)
Subject with prior hematopoietic cell transplant or subject anticipated to receive a
hematopoietic cell transplant during the 24 weeks from the date of randomization. 7
Subject with stroke, myocardial infarction, deep venous thrombosis, pulmonary or
arterial embolism within 6 months immediately up to the date of randomization
Subject with major surgery within 2 months up to the date of randomization. Subject must
have completely recovered from any previous surgery immediately up to the date of
Subject with a major bleeding event (defined as symptomatic bleeding in a critical area
or organ and/or bleeding causing a decrease in Hgb of ≥ 2 g/dL or leading to transfusion of
≥ 2 units of packed red cells) in the last 6 months prior to the date of randomization
Subject with inadequately controlled heart disease and/or have a known left ventricular
ejection fraction < 35%
Subject with uncontrolled systemic fungal, bacterial, or viral infection (defined as
ongoing signs/symptoms related to the infection without improvement despite appropriate
antibiotics, antiviral therapy, and/or other treatment)
Subject with known human immunodeficiency virus (HIV), evidence of active Hepatitis B
(HepB) as demonstrated by the presence of Hepatitis B surface antigen (HBsAg) and/or
positive for Hepatitis B virus DNA (HBVDNA-positive), and/or evidence of active Hepatitis C
(HepC) as demonstrated by a positive Hepatitis C virus RNA (HCV-RNA) test of sufficient
Subject with prior therapy of luspatercept or sotatercept. 14.Subject with history of
severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or
excipients in the investigational product
Pregnant or breastfeeding females. 16.Subject participation in any other clinical
protocol or investigational trial that involves use of experimental therapy (including
investigational agents) and/or therapeutic devices within 30 days or for investigational
agents within five half-lives, whichever comes later, immediately up to the date of
Subject with any significant medical condition, laboratory abnormality, psychiatric
illness, or is considered vulnerable by local regulations (eg, imprisoned or
institutionalized) that would prevent the subject from participating in the study or places
the subject at unacceptable risk if he/she were to participate in the study. 18.Subject
with any condition or concomitant medication that confounds the ability to interpret data
from the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note